A spectrophotometric method for the determination of doxycycline (DOX) is described. The method is based on the formation of blue colored chromogen due to reduction of tungstate and/or molybdate in Folin-Ciocalteu (F-C) reagent by DOX in alkaline medium. The colored species has an absorption maximum at 770 nm and the system obeys Beer's law over the concentration range 0.75-12.0 μg mL-1 DOX. The apparent molar absorptivity is 2.78 × 104 L mol-1 cm-1. The limit of quantification and detection values are reported to be 0.20 and 0.08 μg mL-1, respectively. Over the linear range applicable, the accuracy and precision of the method were evaluated on intra-day and inter-day basis. The reported mean accuracy value was 101.0 ± 1.7 %, the relative error was ≤ 2.7 % and the relative standard deviation was ≤ 2.5 %. Application of the proposed method to bulk powder and commercial pharmaceutical tablets is also presented. No significant difference was obtained between the results of the proposed method and the official BP method. The procedure described in this paper is simple, rapid, accurate and precise.
Keywords
- doxycycline hyclate
- Folin-Ciocalteu reagent
- spectrophotometry
Anti-inflammatory and immunomodulatory effects of rosuvastatin in patients with low-to-moderate cardiovascular risk Promising inhibitors against main protease of SARS CoV-2 from medicinal plants: In silico identificationChemical composition, antioxidant, antimicrobial and antiviral activities of the leaf extracts of Syzygium myrtifolium Beneficial effects of the fructus Sophorae extract on experimentally induced osteoporosis in New Zealand white rabbitsMedicinal plants with anti-SARS-CoV activity repurposing for treatment of COVID-19 infection: A systematic review and meta-analysis The history, current state and perspectives of aerosol therapy Potential of germanium-based compounds in coronavirus infection A green approach to the analysis of co-administered ampicillin/sulbactam and paracetamol in human urine Current strategies in diagnostics and therapeutics against novel coronavirus disease (COVID-19) Isolation of MDCK cells with low expression of mdr1 gene and their use in membrane permeability screening
